TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Laekna, Inc. ( (HK:2105) ).
Laekna, Inc. announced significant progress in its clinical trials for LAE102, a monoclonal antibody targeting obesity. The company completed a Phase I study in China, demonstrating promising results in muscle preservation and weight control, and has initiated a multiple ascending dose study. Additionally, Laekna has partnered with Eli Lilly to accelerate global clinical development, with a U.S. Phase I trial underway. These developments position Laekna as a key player in obesity treatment innovation, potentially impacting its market presence and offering new options for patients.
The most recent analyst rating on (HK:2105) stock is a Buy with a HK$26.46 price target. To see the full list of analyst forecasts on Laekna, Inc. stock, see the HK:2105 Stock Forecast page.
More about Laekna, Inc.
Laekna, Inc. is a biopharmaceutical company focused on the development of innovative therapies, particularly in the field of monoclonal antibodies targeting ActRII receptors. The company is engaged in clinical and pre-clinical candidate development, aiming to provide novel treatment options for conditions such as obesity.
Average Trading Volume: 4,868,500
Technical Sentiment Signal: Strong Buy
Find detailed analytics on 2105 stock on TipRanks’ Stock Analysis page.